Since the launch of the precision medical program in China in 2015, the field of gene sequencing has rapidly developed. 11 of the companies are publicly listed. From a detailed analysis of invested money, over 75 % of these companies have received investments between millions and 100 millions of Yuan. As the rate of company formation increased year by year, some experts fear that a “gene sequencing bubble” might eventually develop.

China Bio news release, May 9, 2017